AI and machine learning are revolutionizing healthcare, especially in the realm of medical devices, bringing in new ways to diagnose and treat patients. But with this fast-paced innovation comes the tricky task of regulating technology that’s constantly evolving.
Agencies like the FDA in the U.S. and regulatory bodies in Europe are working to keep up, finding ways to make sure these high-tech tools are safe, reliable, and effective. By creating flexible guidelines, building collaborative partnerships, and focusing on real-world monitoring, regulators are adapting to the unique challenges of AI-driven healthcare—aiming to support innovation while keeping patient safety front and center.
Differences in Regulatory Approaches to AI in Healthcare: US vs. Europe
1. Regulatory Structure and Oversight
United States: In the U.S., the Food and Drug Administration (FDA) is the main body overseeing AI in medical devices. It operates under a centralized system with clear processes for classifying devices, assessing risks, and approving them. The FDA’s Digital Health Center of Excellence focuses on AI and machine learning (ML) in healthcare, offering resources and guidance for developers. The FDA itself reviews medical AI devices to make sure they’re safe and effective.
Europe: The European Union (EU) and the United Kingdom (UK) follow a more decentralized system, using third-party certifying bodies for conformity assessments instead of direct government oversight. The EU’s regulatory framework is developed by the European Commission, aiming to create consistent regulations across member states for a smooth internal market. In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) works with the Department of Health to oversee AI in healthcare.
“Unlike in America, we don’t really have a single agency overseeing medical devices development in Europe… The European Commission drives the policy, aiming for harmonization across member states to support a single market.“
Lincoln Tsang, a UK-based legal expert
2. Risk-Based Frameworks for Classification
US FDA: The FDA categorizes AI-based medical devices by their risk level and intended use, with a focus on potential patient impact. Lower-risk devices, like general wellness apps, face minimal oversight, while higher-risk tools, particularly those that influence clinical decisions, go through strict evaluation. The FDA’s guidance highlights functionality, deployment context, and patient safety as key factors in deciding the risk level and regulatory needs.
European and UK Standards: Similar to the FDA, regulators in Europe and the UK classify devices based on functionality, intended use, and patient impact. Both the EU and UK use a risk-based approach to assess whether AI software qualifies as a medical device, examining the potential harm and healthcare role of the device. Unlike the FDA’s centralized model, the EU uses third-party bodies for assessments, adding industry involvement to the review process.
3. Approval Pathways and Compliance Assistance
The FDA offers several resources to help developers, including guidance documents, informal consultations, and a Digital Health Policy Navigator to clarify regulatory requirements. A key tool is the Predetermined Change Control Plan (PCCP), which lets developers update AI models without resubmitting for approval, as long as updates follow pre-approved guidelines.
The EU and UK support emerging tech through policy papers and adaptable guidelines. While EU regulators are considering adaptive AI-specific regulation, they currently use general guidance rather than structured pathways like the FDA’s PCCP. Both regions prioritize flexibility, updating guidelines and consulting with industry to keep up with rapid tech advancements in AI and digital health.
“We understand the impact this has on companies, particularly for smaller companies and startups, which we see a lot of in the digital health space. Predictability in regulation is crucial.”
Sonja Fulmer, Deputy Director, Digital Health Center of Excellence
4. International Harmonization Efforts
Recognizing the global reach of AI, the FDA, Health Canada, and the UK’s MHRA collaborate to align standards and practices. This teamwork simplifies the approval process for companies across borders. Through groups like the International Medical Device Regulators Forum (IMDRF), these agencies work on creating standards that support global interoperability, safety, and clarity. The IMDRF also offers guidance on issues like machine learning practices, promoting a unified regulatory approach worldwide.
Third-Party Compliance Audits for Healthcare Startups
Third-party compliance audits are key for healthcare startups to ensure their products meet regulatory standards before hitting the market. Companies like Gart Solutions offer specialized compliance audits and consulting services to help startups align with the rules set by bodies like the FDA in the U.S. and certification organizations in the EU.
These third-party services support startups by helping them:
Assess Regulatory Readiness
Through preliminary audits and gap assessments, firms like Gart Solutions help startups identify their current compliance status and highlight areas needing improvement.
Prepare for Formal Certification
By simulating official audit conditions, third-party firms enable startups to address potential issues in advance of formal evaluations by agencies like the FDA or European certifying bodies.
Monitor Ongoing Compliance
Since regulations, particularly around adaptive AI, are constantly evolving, third-party auditors often conduct periodic reviews to ensure products stay compliant. For AI-enabled devices, these audits can also include checks on algorithmic fairness, data quality, and post-market performance.
Benefits of Compliance Audits for Startups
Partnering with third-party compliance firms offers several advantages:
- Cost Savings: Catching compliance issues early can prevent expensive delays and rework during regulatory approval.
- Streamlined Approvals: A thorough pre-audit can smooth the formal certification process, reducing friction with regulatory bodies.
- Increased Trust and Transparency: Third-party audits show a startup’s dedication to safety and transparency, boosting stakeholder and consumer confidence.
In regions like the EU, where third-party assessments are a regulatory standard, companies like Gart Solutions help fill the gap for startups that may not have in-house compliance expertise. This support is especially valuable for AI-driven healthcare startups, where standards are both strict and rapidly changing.
Why Postmarket Surveillance Matters
Postmarket surveillance plays a vital role in regulating AI in medical devices. For high-stakes uses like sepsis detection tools, the FDA requires a monitoring plan to track real-world performance, ensuring devices remain safe and effective across diverse patient populations. This process means manufacturers need to keep an eye on model bias, data quality, and overall device performance in everyday clinical settings. By actively managing these factors, postmarket surveillance helps reduce risks from data issues or model bias, supporting consistent, reliable performance over time.
Trends and the Future of Regulation
With AI becoming a bigger part of healthcare, regulators are likely to move toward more flexible, adaptive policies. Emerging challenges, like continuous-learning AI algorithms, are pushing agencies to rethink how they manage the entire lifecycle of these technologies. Quality assurance, postmarket surveillance, and adaptable regulations are all set to play a larger role as AI advances.
The FDA is working on guidelines for adaptive AI, expected to be released soon, which will help developers as they build continuously learning algorithms. Meanwhile, regulatory bodies in the UK and EU are exploring similar frameworks suited to their own standards, promoting international alignment and consistency.
Conclusion
The regulatory landscape for AI in healthcare is advancing rapidly to keep pace with technological developments. With their risk-based frameworks, both the FDA and European regulators are focused on ensuring the safety and efficacy of AI-enabled medical devices while supporting innovation. Through resources like the Digital Health Center of Excellence and international harmonization initiatives, agencies are setting the stage for a future where AI can safely and effectively transform healthcare, with robust postmarket surveillance and flexible change management strategies forming the backbone of this evolving regulatory framework.
See how we can help to overcome your challenges
